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Loci Associated with N-Glycosylation of Human
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Abstract
Glycosylation of immunoglobulin G (IgG) influences IgG effector function by modulating binding to Fc receptors. To identify genetic
loci associated with IgG glycosylation, we quantitated N-linked IgG glycans using two approaches. After isolating IgG from human
plasma, we performed 77 quantitative measurements of N-glycosylation using ultra-performance liquid chromatography (UPLC) in
2,247 individuals from four European discovery populations. In parallel, we measured IgG N-glycans using MALDI-TOF mass
spectrometry (MS) in a replication cohort of 1,848 Europeans. Meta-analysis of genome-wide association study (GWAS) results
identified 9 genome-wide significant loci (P,2.2761029) in the discovery analysis and two of the same loci (B4GALT1 and MGAT3) in
the replication cohort. Four loci contained genes encoding glycosyltransferases (ST6GAL1, B4GALT1, FUT8, and MGAT3), while the
remaining 5 contained genes that have not been previously implicated in protein glycosylation (IKZF1, IL6ST-ANKRD55, ABCF2SMARCD3, SUV420H1, and SMARCB1-DERL3). However, most of them have been strongly associated with autoimmune and
inflammatory conditions (e.g., systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, Crohn’s disease, diabetes type 1,
multiple sclerosis, Graves’ disease, celiac disease, nodular sclerosis) and/or haematological cancers (acute lymphoblastic leukaemia,
Hodgkin lymphoma, and multiple myeloma). Follow-up functional experiments in haplodeficient Ikzf1 knock-out mice showed the
same general pattern of changes in IgG glycosylation as identified in the meta-analysis. As IKZF1 was associated with multiple IgG Nglycan traits, we explored biomarker potential of affected N-glycans in 101 cases with SLE and 183 matched controls and
demonstrated substantial discriminative power in a ROC-curve analysis (area under the curve = 0.842). Our study shows that it is
possible to identify new loci that control glycosylation of a single plasma protein using GWAS. The results may also provide an
explanation for the reported pleiotropy and antagonistic effects of loci involved in autoimmune diseases and haematological cancer.
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conducted analyses, so both were used - one in each available
cohort. We performed 77 quantitative measurements of IgG Nglycosylation using ultra performance liquid chromatography
(UPLC) in 2247 individuals from four European discovery
populations (CROATIA-Vis, CROATIA-Korcula, ORCADES,
NSPHS). In parallel, we measured IgG N-glycans using MALDITOF mass spectrometry (MS) in 1848 individuals from another
European population (Leiden Longevity Study (LLS)). Descriptions of these population cohorts are found in Table S11. Aiming
to identify genetic loci involved in IgG glycosylation, we
performed a GWA study in both cohorts. Associations at 9 loci
reached genome-wide significance (P,2.2761029) in the discovery meta-analysis and at two loci in the replication cohort. The
two loci identified in the latter cohort were associated with the
analogous glycan traits in the former cohort as detailed in the
subsection ‘‘Replication of our findings’’. Both UPLC and MS
methods for quantitation of N-glycans were found to be amenable
to GWA studies. Since our UPLC study gave a considerably
greater yield of significant findings in comparison to MS study, the
majority of our results section focuses on the findings from the
discovery population cohort, which was studied using the UPLC
method.
Among the nine loci that passed the genome-wide significance
threshold, four contained genes encoding glycosyltransferases
(ST6GAL1, B4GALT1, FUT8 and MGAT3), while the remaining
five loci contained genes that have not been implicated in protein
glycosylation previously (IKZF1, IL6ST-ANKRD55, ABCF2SMARCD3, SUV420H1-CHKA and SMARCB1-DERL3). As a rule,
the implicated genes were associated with several N-glycan traits.
The explanation and notation of the 77 N-glycan measures is
presented in Table S1. It comprises 23 directly measured
quantitative IgG glycosylation traits (shown in Figure 1) and 54
derived traits. Descriptive statistics of these measures in the
discovery cohorts are presented in Table S2. GWA analysis was
performed in each of the populations separately and the results
were combined in an inverse-variance weighted meta-analysis.
Summary data for each gene region showing genome-wide
association (p,27.261029) or found to be strongly suggestive
(2.2761029,p,561028) are presented in Table 1. Summary
data for all single-nucleotide polymorphisms (SNPs) and traits with
suggestive associations (p,161025) are presented in Table S3,
with population-specific and pooled genomic control (GC) factors
reported in Table S4.
The most statistically significant association was observed in a
region on chromosome 3 containing the gene ST6GAL1 (Table 1,
Figure S1A). ST6GAL1 codes for the enzyme sialyltransferase 6
which adds sialic acid to various glycoproteins including IgG
glycans (Figure 2), and is therefore a highly biologically plausible
candidate. In this region of about 70 kilobases (kb) we identified
37genome-wide significant SNPs associated with 14 different IgG
glycosylation traits, generally reflecting sialylation of different
glycan structures (Table 1). The strongest association was observed
for the percentage of monosialylation of fucosylated digalactosylated structures in total IgG glycans (IGP29, see Figure 1 and
Table S1 for notation), for which a SNP rs11710456 explained
17%, 16%, 18% and 3% of the trait variation for CROATIA-Vis,

Introduction
Glycosylation is a ubiquitous post-translational protein modification that modulates the structure and function of polypeptide
components of glycoproteins [1,2]. N-glycan structures are
essential for multicellular life [3]. Mutations in genes involved in
modification of glycan antennae are common and can lead to
severe or fatal diseases [4]. Variation in protein glycosylation also
has physiological significance, with immunoglobulin G (IgG) being
a well-documented example. Each heavy chain of IgG carries a
single covalently attached bi-antennary N-glycan at the highly
conserved asparagine 297 residue in each of the CH2 domains of
the Fc region of the molecule. The attached oligosaccharides are
structurally important for the stability of the antibody and its
effector functions [5]. In addition, some 15–20% of normal IgG
molecules have complex bi-antennary oligosaccharides in the
variable regions of light or heavy chains [6,7]. 36 different glycans
(Figure 1) can be attached to the conserved Asn297 of the IgG
heavy chain [8,9], leading to hundreds of different IgG isomers
that can be generated from this single glycosylation site.
Glycosylation of IgG has important regulatory functions. The
absence of galactose residues in association with rheumatoid
arthritis was reported nearly 30 years ago [10]. The addition of
sialic acid dramatically changes the physiological role of IgGs,
converting them from pro-inflammatory to anti-inflammatory
agents [11,12]. Addition of fucose to the glycan core interferes
with the binding of IgG to FccRIIIa and greatly diminishes its
capacity for antibody dependent cell-mediated cytotoxicity
(ADCC) [13,14]. Structural analysis of the IgG-Fc/FccRIIIa
complex has demonstrated that specific glycans on FccRIIIa are
also essential for this effect of core-fucose [15] and that removal of
core fucose from IgG glycans increases clinical efficacy of
monoclonal antibodies, enhancing their therapeutic effect through
ADCC mediated killing [16–18].
New high-throughput technologies, such as high/ultra performance liquid chromatography (HPLC/UPLC), MALDI-TOF
mass spectrometry (MS) and capillary electrophoresis (CE), allow
us to quantitate N-linked glycans from individual human plasma
proteins. Recently, we performed the first population-based study
to demonstrate physiological variation in IgG glycosylation in
three European founder populations [19]. Using UPLC, we
showed exceptionally high individual variability in glycosylation of
a single protein - human IgG - and substantial heritability of the
observed measurements [19]. In parallel, we quantitated IgG Nglycans in another European population (Leiden Longevity Study
– LLS) by mass spectrometry. In this study, we combined those
high-throughput glycomics measurements with high-throughput
genomics to perform the first genome wide association (GWA)
study of the human IgG N-glycome.

Results
Genome-wide association study and meta-analysis
We separated a single protein (IgG) from human plasma and
quantitated its N-linked glycans using two state-of-the-art technologies (UPLC and MALDI-TOF MS). Their comparative advantages in GWA studies were difficult to predict prior to the
PLOS Genetics | www.plosgenetics.org
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of the variance explained in this particular population (estimated
as 3%). Although the allele frequency is similar between all
populations, in the forest plot (Figure S1A) although NSPHS does
overlap with the other populations, the 95% CI is much larger. It
is also possible that there are population-specific genetic and/or
environmental differences in NSPHS that are affecting the amount
of variance explained by this SNP. After analysis conditioning on
the top SNP (rs11710456) in this region, the SNP rs7652995 still
reached genome-wide significance (p = 4.15610213). After adjusting for this additional SNP, the association peak was completely
removed. This suggests that there are several genetic factors
underlying this association. Conditional analysis of all other
significant and suggestive regions resulted in the complete removal
of the association peak.
We also identified 28 SNPs showing genome-wide significant
associations with 11 IgG glycosylation traits (2.70610211,
p,4.7361028) at a locus on chromosome 9 spanning over
60 kb (Figure S1B). This region includes B4GALT1, which codes
for the galactosyltransferase responsible for the addition of
galactose to IgG glycans (Figure 2). The glycan traits showing
genome-wide association included the percentage of FA2G2S1 in
the total fraction (IGP17), the percentage of FA2G2 in the total
and neutral fraction (IGP13, IGP53), the percentage of sialylation
of fucosylated structures without bisecting GlcNAc (IGP24,
IGP26), the percentage of digalactosylated structures in the total
neutral fraction (IGP57) and, in the opposite direction, the
percentage of bisecting GlcNAc in fucosylated sialylated structures
(IGP36–IGP40).

Author Summary
After analysing glycans attached to human immunoglobulin G in 4,095 individuals, we performed the first genomewide association study (GWAS) of the glycome of an
individual protein. Nine genetic loci were found to
associate with glycans with genome-wide significance. Of
these, four were enzymes that directly participate in IgG
glycosylation, thus the observed associations were biologically founded. The remaining five genetic loci were not
previously implicated in protein glycosylation, but the
most of them have been reported to be relevant for
autoimmune and inflammatory conditions and/or haematological cancers. A particularly interesting gene, IKZF1 was
found to be associated with multiple IgG N-glycans. This
gene has been implicated in numerous diseases, including
systemic lupus erythematosus (SLE). We analysed Nglycans in 101 cases with SLE and 183 matched controls
and demonstrated their substantial biomarker potential.
Our study shows that it is possible to identify new loci that
control glycosylation of a single plasma protein using
GWAS. Our results may also provide an explanation for
opposite effects of some genes in autoimmune diseases
and haematological cancer.

CROATIA-Korcula, ORCADES and NSPHS respectively (metaanalysis p = 6.12610275). NSPHS had a very small sample size in
this analysis (N = 179) and may not provide an accurate portrayal

Figure 1. Structures of glycans separated by HILIC-UPLC analysis of the IgG glycome.
doi:10.1371/journal.pgen.1003225.g001
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Table 1. A complete list of genetic markers that showed genome-wide significant (P,2.27E-9) or strongly suggestive (P#5E-08) association with glycosylation of Immunoglobulin
G analysed by UPLC in the discovery meta-analysis.
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Figure 2. A summary of changes to IgG N-glycan structures that were associated with 16 loci identified through GWA study.
doi:10.1371/journal.pgen.1003225.g002

17 IgG glycosylation traits (Figure S1D). Association was strongest
between SNP rs909674 and the incidence of bisecting GlcNAc in
all fucosylated disialylated structures (IGP40, p = 9.66610225) and
the related ratio IGP39 (p = 8.87610224). In summary, this locus
contained variants influencing levels of fucosylated species and the
ratio between fucosylated (especially disialylated) structures with
and without bisecting GlcNAc (Figure 2). Since MGAT3 codes for
the enzyme N-acetylglucosaminyltransferase III (beta-1,4-mannosyl-glycoprotein-4-beta-N-acetylglucosaminyltransferase), which is
responsible for the addition of bisecting GlcNAc to IgG glycans,
this gene is the most biologically plausible candidate.
Bioinformatic analysis of known and predicted protein-protein
interactions using String 9.0 software (http://string-db.org/)
showed that interactions between the clusters of FUT8B4GALT1-MGAT3 genes and ST6GAL1-B4GALT1-MGAT3 genes
had high confidence score: FUT8-B4GALT1 of 0.90; FUT8MGAT3 of 0.95; ST6GAL1-B4GALT1 of 0.90; and ST6GAL1-

A large (541 kb) region on chromosome 14 harbouring the
FUT8 gene contained 167 SNPs showing significant associations
with 12 IgG glycosylation traits reflecting fucosylation of IgG
glycans (Figure S1C). FUT8 codes for fucosyltransferase 8, an
enzyme responsible for the addition of fucose to IgG glycans
(Figure 2). The strongest association (1.08610222,p,
2.60610217) was observed with the percentage of A2 glycans in
total and neutral fractions (IGP2, IGP42) and for derived traits
related to the proportion of fucosylation (IGP58, IGP59 and
IGP61; all in the opposite direction). In summary, SNPs at the
FUT8 locus influence the proportion of fucosylated glycans, and,
in the opposite direction, the percentages of A2, A2G1 and A2G2
glycans which are not fucosylated.
On chromosome 22, two loci were associated with IgG
glycosylation. The first region, containing SYNGR1-TAB1MGAT3-CACNA1I genes, spans over 233 kb. This region harboured 60 SNPs showing genome-wide significant association with

PLOS Genetics | www.plosgenetics.org
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IL6ST-ANKRD55 was significantly associated (6.88610211,p,
2.3961029) with six IgG glycosylation traits, including FA2 and
FA2G2 in total and neutral fractions (IGP3, IGP13, IGP43,
IGP53) and the percentage of agalactosylated and digalactosylated
structures in total neutral IgG glycans (IGP55, IGP57) (Figure 2).
The protein encoded by IL6ST is a signal transducer shared by
many cytokines, including interleukin 6 (IL6), ciliary neurotrophic
factor (CNTF), leukaemia inhibitory factor (LIF), and oncostatin
M (OSM). Variants in IL6ST have been associated with
rheumatoid arthritis and multiple myeloma, but also with
components of metabolic syndrome [44–46].
The chromosome 7 SNP rs2072209 located in LAMB1 was
strongly suggestively associated with the percentage of fucosylation
of digalactosylated (with bisecting GlcNAc) structures (IGP69;
p = 1.1661028) (Figure 2). LAMB1 (laminin beta 1) is a member of
a family of extracellular matrix glycoproteins that are the major
non-collagenous constituent of basement membranes. It is thought
to mediate the attachment, migration and organization of cells
into tissues during embryonic development by interacting with
other extracellular matrix components. It has been associated with
ulcerative colitis in several large-scale studies in European and
Japanese populations, suggesting that changes in the integrity of
the intestinal epithelial barrier may contribute to the pathogenesis
of the disease [47–51] (Table 2).
Another particularly interesting finding was the suggestive
association between rs404256 in the BACH2 gene on chromosome
6 and IGP7, defined through proportional contribution of
FA2[6]G1 in all IgG glycans (p = 7.4961029). BACH2 is B-cellspecific transcription factor that can act as a suppressor or
promoter; among many known functions, it has been shown to
‘‘orchestrate’’ transcriptional activation of B-cells, modify the
cytotoxic effects of anticancer drugs and regulate IL-2 expression
in umbilical cord blood CD4+ T cells [52]. BACH2 has been
previously associated with a spectrum of diseases with autoimmune
component: type 1 diabetes [53–56], Graves’ disease [57], celiac
disease [58], Crohn’s disease [21] and multiple sclerosis [59]
(Table 2).
The chromosome 11 SNP rs4930561 located in the SUV420H1CHKA gene was associated with percentage of FA1 in neutral
(IGP41; p = 8.88610210) and total (IGP1; p = 1.3061028) fractions of IgG glycans. SUV420H1 codes for histone-lysine Nmethyltransferase which specifically trimethylates lysine 20 of
histone H4 and could therefore affect activity of many different
genes; it is thought to be involved in proviral silencing in somatic
and germ line cells through epigenetic mechanisms [60]. CHKA
has a key role in phospholipid biosynthesis and may contribute to
tumour cell growth. We recently reported a number of strong
associations between lipidomics and glycomics traits in human
plasma [61]. Thus, an enzyme involved in phospholipid synthesis
is also a possible candidate because the lipid environment is known
to affect glycosyltransferases activity [61].
Three further loci were identified as strongly suggestive through
GWAS and deserve attention for their possible pleiotropic effects.
SNP rs9296009 in PRRT1 (proline-rich transmembrane protein 1)
was associated with IGP23 (p = 3.79610208) while variants in
PRRT1 previously showed associations with nodular sclerosis and
Hodgkin lymphoma [62]. Moreover, rs1049110 in HLA-DQA2HLA-DQB2 was associated with IGP2 and IGP42 (p = 1.64610208
and 4.44610208, respectively). This SNP is in nearly complete
linkage disequilibrium with two other SNPs in this region that have
previously been associated with SLE and hepatitis B [63] (Table 2).
Another SNP in this region has been linked with narcolepsy [64].
Finally, rs7224668 in SLC38A10, a putative sodium-dependent
amino acid/proton antiporter, showed significant association with

MGAT3 of 0.73. The glycosyltranferase genes at the four GWAS
loci - ST6GAL1, B4GALT1, FUT8, and MGAT3 – are responsible
for adding sialic acid, galactose, fucose and bisecting GlcNAc to
IgG glycans, thus demonstrating the proof of principle that a single
protein glycosylation GWAS approach can identify biologically
important glycan pathways and their networks. Interestingly,
ST6GAL1 has been previously associated with Type 2 diabetes
[20], MGAT3 with Crohn’s disease [21], primary biliary cirrhosis
[22] and cardiac arrest [23], and FUT8 with multiple sclerosis,
blood glutamate levels [24] and conduct disorder [25] (Table 2).
We have recently shown changes in plasma N-glycan profile
between patients with attention-deficit hyperactivity disorder
(ADHD), autism spectrum disorders and healthy controls, and
identified loci influencing plasma N-glycome with pleiotropic
effects on ADHD [26,27].

Novel candidate genes involved with N-glycosylation
In addition to four loci containing genes for enzymes known to
be involved in IgG glycosylation, our study also found five
unexpected associations showing genome-wide significance. In the
second region on chromosome 22 we observed genome-wide
significant associations of 10 SNPs with 20 IgG glycosylation traits.
The region spans 49 kb and contains the genes SMARCB1-DERL3
(Figure S1E). The strongest associations (8.63610217,p,
3.00610213) were observed between SNP rs2186369 and the
percentage of FA2[6]BG1 in total and neutral fractions (IGP9,
IGP49) and levels of fucosylated structures with bisecting GlcNAc
(IGP66, IGP68, IGP70, IGP71 in the same direction and IGP72
in the opposite direction). Thus, the SMARCB1-DERL3 locus
appears to specifically influence levels of fucosylated monogalactosylated structures with bisecting GlcNAc (Figure 2). DERL3 is a
promising functional candidate, because it encodes a functional
component of endoplasmic reticulum (ER)-associated degradation
for misfolded luminal glycoproteins [28]. However, SMARCB1 is
also known to be important in antiviral activity, inhibition of
tumour formation, neurodevelopment, cell proliferation and
differentiation [29]. The region has also been implicated in the
regulation of c-glutamyl-transferase (GGT) [30] (Table 2).
A locus on chromosome 7 spanning 26kb contained 11 SNPs
showing genome-wide significant associations with 13 IgG
glycosylation traits (Figure S1F). The strongest association
(p = 1.87610213) was observed between SNP rs6421315 located
in IKZF1 and the percentage of fucosylation of agalactosylated
structures without bisecting GlcNAc (IGP63). Thus, SNPs at this
locus influence the percentage of non-fucosylated agalactosylated
glycans, the fucosylation ratio in agalactosylated glycans (in
opposite directions for glycan species with and without bisecting
GlcNAc), and the ratio of fucosylated structures with and without
bisecting GlcNAc (Figure 2). The IKZF1 gene encodes the DNAbinding protein Ikaros, acting as a transcriptional regulator and
associated with chromatin remodelling. It is considered to be the
important regulator of lymphocyte differentiation and has been
shown to influence effector pathways through control of class
switch recombination [31], thus representing a promising functional candidate [32]. There is overwhelming evidence that IKZF1
variants are associated with childhood acute lymphoblastic
leukaemia [33,34] and several diseases with an autoimmune
component: systemic lupus erythematosus (SLE) [35–37], type 1
diabetes [38,39], Crohn’s disease [40], systemic sclerosis [41],
malaria [42] and erythrocyte mean corpuscular volume [43]
(Table 2).
SNPs at several other loci also showed genome-wide significant
association with a number of different IgG glycosylation traits
(Figure S1G–S1P). Chromosome 5 SNP rs17348299, located in
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rs2072209

LAMB1

rs11847263

rs17348299

IL6ST-ANKRD55

FUT8

rs11710456

rs6421315

IKZF1

ST6GAL1

IgG Glycan
Top SNP

Gene

rs4132601
rs10276619
rs7805803
rs1456893
rs12718597
rs1451375

ALL
Hippocampal
atrophy (AD qt)
Total ventricular
volume (AD qt)
Crohn’s disease
Mean corpuscular
volume
Malaria

rs16861329

rs1256531
rs7158173
rs8007846

Waist Circumference
Multiple Sclerosis - brain
glutamate levels

rs2108225

Ulcerative colitis

rs7159888

rs4730273

Ulcerative colitis

Conduct disorder
(symptom count)

rs4730276

Ulcerative colitis

N-Glycans (DG1)

rs4510766

Ulcerative colitis

rs10483776

rs886774

Ulcerative colitis

N-Glycans (DG6)

rs4598195

rs2158836

Ulcerative colitis

Ulcerative colitis

rs6859219

T2D
Rheumatoid arthritis

rs10937275

Drug-induced liver
injury (flucloxacillin)

rs10272724

rs11978267

ALL

T1D

rs4917014

SLE

rs1240874

rs2366293

Systemic sclerosis

rs921916

SLE

Top Disease
SNP

SLE

Disease

–

–

–

A

G

A

–

–

A

G

A

A

C

G

–

C

–

–

A

A

–

–

C

G

A

G

C

Risk
Allele

9.00E-06

4.00E-06

4.00E-06

3.00E-18

1.00E-08

1.00E-07

5.00E-06

9.00E-06

2.00E-16

3.00E-08

8.00E-08

7.00E-06

1.00E-11

3.00E-08

1.00E-08

1.10E-11

1.00E-06

6.00E-06

5.00E-13

5.00E-09

9.00E-06

3.00E-06

1.00E-19

8.00E-11

3.00E-23

2.33E-09

2.00E-06

P-Value

Baranzini et al Brain 2010

Polasek et al Croat Med J 2009

Dick et al Mol Psychiatry 2010

Lauc et al PLoS Genet 2010

Lauc et al PLoS Genet 2010

Asano et al Nat Genet 2009

Silverberg et al Nat Genet 2009

Silverberg et al Nat Genet 2009

Anderson et al Nat Genet 2011

Barrett et al Nat Genet 2009

McGovern et al Nat Genet 2010

Silverberg et al Nat Genet 2009

Stahl et al Nat Genet 2010

Kooner et al Nat Genet 2011

Daly et al Nat Genet 2009

Swafford et al Diabetes 2011

Gorlova et al PLoSGenet 2011

Jallow et al Nat Genet 2009

Ganesh et al Nat Genet 2009

Barrett et al Nat Genet 2008

Furney et al Mol Psychiatry 2010

Potkin et al PLoS One 2009

Papeammanuil et al Nat Genet 2009

Trevino et al Nat Genet 2009

Han et al Nat Genet 2009

Cunninghame Graham et al PLoS Genet 2011

Gateva et al Nat Genet 2009

Reference

0.021

0.714

0.369

0.024

0.032

–

–

0.031

0.071

0.027

0.012

0.011

0

0.002

–

0.014

0.018

0.011

0.071

0

0.002

0.002

0.001

0.030

American

European

0.196

0.011

0.388

0.571

0.182

0.796

1

0.864

0.548

1.000

–

–

0.733

0.807

0.716

0.487

0.221

0.048

0.047

–

0.204

0.181

0.117

0.280

0.005

0.047

0.047

0.040

0.484

0.070

0.261

0.002

0.071

0.727

0.416

0.017

0.027

0.038

0.107

0.067

0.115

0.055

0.044

0.000

0.017

0.012

–

0.002

0.019

0

0.087

0

0.012

0.012

0.053

0.057

0.692

0.081

1

1

0.758

0.482

0.931

0.534

1.000

1.000

1.000

1.000

1.000

0.005

1

0.130

–

0.097

0.161

0.007

0.332

0.013

0.130

0.130

0.277

0.748

0.771

D9

1000G Pilot 1
R2

R2
D9

HapMap 2

European,
0.092
African, other

European

European

Japanese

European

European

European

European

European

European

European

South Asian

European

European

European

Gambian

European

European

European

European

European

European

Han Chinese

European

European

Ancestry

Table 2. An analysis of pleiotropy between loci associated with IgG glycans and previously reported disease/trait susceptibility loci, with linkage disequilibrium computed
between the most significantly associated SNPs.
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rs7224668

rs2413583

Crohn’s disease

rs11755527
rs1847472
rs12212193

T1D
Crohn’s disease
Multiple Sclerosis
rs10445407

rs11755527

T1D

Longevity

rs11755527

rs3757247

T1D
T1D

rs10806425

Celiac disease

Narcolepsy
rs370409

rs7453920
rs2858884

Hepatitis B

Graves’ disease

rs2301271

rs1061808

Phospholipid levels
SLE

rs204999

Nodular sclerosis
Hodgkin lymphoma

rs2739330

rs968451

Primary biliary cirrhosis

GGT

rs54211

Top Disease
SNP

Sudden cardiac arrest

Disease

–

G

G

G

–

G

A

A

T

A

G

T

–

–

T

C

T

–

Risk
Allele

1.00E-06

4.00E-08

5.00E-09

5.00E-12

5.00E-08

3.00E-08

1.00E-06

4.00E-10

2.00E-06

3.00E-08

6.00E-28

2.00E-12

8.00E-10

8.00E-18

2.00E-09

1.00E-26

1.00E-09

8.00E-07

P-Value

Yashin et al Aging 2010

Sawcer et al Nature 2011

Franke et al Nat Genet 2010

Cooper et al Nat Genet 2008

Barrett et al Nat Genet 2009

Plagnol et al PLoSGenet 2011

Grant et al Diabetes 2009

Dubois et al Nat Genet 2010

Chu et al Nat Genet 2011

Hor et al Nat Genet 2010

Mbarek et al Hum Mol Genet 2011

Chung et al PLoS Genet 2011

Demirkan et al PLoS Genet 2012

Cozen et al Blood 2012

Chambers et al Nat Genet 2011

Franke et al Nat Genet 2010

Mells et al Nat Genet 2011

Aouizerat et al BMC Car Diso 2011

Reference

European

European

European

European

European

European

European

European

Chinese

European

Japanese

European

European

European

European

European

European

European

Ancestry

0.714

0.001

0

0.031

0.031

0.031

0.039

0.005

0.010

0.193

0.967

0.967

0.137

0.125

0.009

0.043

0.041

0.053

R

2

1

0.036

0.011

0.186

0.186

0.186

0.196

0.103

0.187

1

1

1

0.626

1

0.255

0.313

0.682

0.362

D9

HapMap 2

0.692

0.027

0.009

0.031

0.031

0.031

0.042

0.006

0.009

–

–

–

–

–

0

0.053

0.080

0.043

R2

1

0.166

0.124

0.179

0.179

0.179

0.204

0.09

0.166

–

–

–

–

–

0.012

0.292

1

0.360

D9

1000G Pilot 1

Associations are those found in the GWAS Catalog track of USCS Genome browser (accessed 04/07/2012) and LD has been calculated using SNAP (http://www.broadinstitute.org/mpg/snap/;Johnson, A. D., Handsaker, R. E., Pulit, S.,
Nizzari, M. M., O’Donnell, C. J., de Bakker, P. I. W. SNAP: A web-based tool for identification and annotation of proxy SNPs using HapMap Bioinformatics, 2008 24(24):2938–2939).
doi:10.1371/journal.pgen.1003225.t002

SLC38A10

rs404256

BACH2

rs9296009

PRRT1

rs1049110

rs2186369

SMARCB1-DERL3

HLA-DQA2 - HLADQB2

rs909674

IgG Glycan
Top SNP

SYNGR1-TAB1MGAT3-CACNA1I

Gene
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IGP31 (p = 3.33610208). Although the function of this gene is not
understood, it has been associated with autism and longevity
[65,66].
The remaining three signals implicated ABCF2-SMARCD3 region
(rs1122979 was associated with IGP 2, 5, 42, 45, with p-value
ranging between 2.10610210,p,1.8961029), RECK (rs4878639
was suggestively associated with IGP17; p = 3.5161028) and PEX5
(rs12828421 suggestively associated with IGP41; p = 4.4861028).
The function of ABCF2 (ATP-binding cassette, sub-family F,
member 2) is not well understood. SMARCD3 stimulates nuclear
receptor mediated transcription; it belongs to the neural progenitors-specific chromatin remodelling complex (npBAF complex) and
the neuron-specific chromatin-remodelling complex (nBAF complex). RECK is known to be a strong suppressor of tumour invasion
and metastasis, regulating metalloproteinases which are involved in
cancer progression. PEX 5 binds to the C-terminal PTS1-type
tripeptide peroxisomal targeting signal and plays an essential role in
peroxisomal protein import (www.genecards.org).

Since glycan traits associated with IKZF1 were related to the
presence and absence of core-fucose and bisecting GlcNAc, we
analysed the promoter region of MGAT3 (codes for enzyme that
adds bisecting GlcNAc to IgG glycans) in silico and identified two
binding sites for IKZF1 that were conserved between humans
and mice, while recognition sites for IKZF1 were not found in the
promoter region of FUT8 (which codes for an enzyme that adds
core-fucose to IgG glycans). Since the promoter regions of
MGAT3 were conserved between humans and mice, we used
Ikzf1 knockout mice [68] as a model to study the effects of IKZF1
deficiency on IgG glycosylation. IgG was isolated from the
plasma of 5 heterozygous knockout mice and 5 wild-type
controls. The summary of the results of IgG glycosylation
analysis is presented in Table 3, while complete results are
presented in Table S7. We observed a number of alterations in
glycome composition that were all consistent with the role of
IKZF1 in the down-regulation of fucosylation and up-regulation
of the addition of bisecting GlcNAc to IgG glycans; 12 out of 77
IgG N-glycans measures showed statistically significant difference (p,0.05) between wild type and heterozygous Ikzf1 knockouts, where 5 mice from each group were compared (Table 3).
The empirical version of Hotelling’s test demonstrated global
significance (p = 0.03) of difference between distributions of IgG
glycome between wild type and Ikzf1 knock-out mice, where 5
mice from each group were compared. While the tests for
differences between individual glycome measurements did not
reach strict statistical significance after conservative Bonferroni
correction (p = 0.05/77 = 0.0006), we observed that 12 out of 77
(15%) IgG N-glycans measures showed nominally significant
difference (p,0.05) between wild type and heterozygous Ikzf1
knock-outs (Table 3). Significant results from the global
difference test ensure that difference between the two groups
does exist, and it is most likely due to the difference between (at
least some of) the measurements which demonstrated nominal
significance. Observed alterations in glycome composition were
all consistent with the role of IKZF1 in the down-regulation of
fucosylation and up-regulation of the addition of bisecting
GlcNAc to IgG glycans.

Results from an independent cohort using MS
quantitation method
The parallel effort in the outbred Leiden Longevity Study (LLS)
was based on a different N-glycan quantitation method (MS). While
UPLC groups glycans according to structural similarities, MS groups
them by mass. Furthermore, MS analysis focused on Fc glycans
while UPLC measures both Fc and Fab glycans, thus traits measured
by the two methods could not have been directly compared.
Glycosylation patterns of IgG1 and IgG2 were investigated by
analysis of tryptic glycopeptides, with six glycoforms per IgG subclass
measured. The intensities of all glycoforms were related to the
monogalactosylated, core-fucosylated biantennary species, providing
five relative intensities registered per IgG subclass (Tables S5 and
S6). The analysis identified two loci as genome-wide significant implicating MGAT3 (p = 1.6610210 for G1FN, analogous to UPLC
IGP9; p = 3.1261028 for G0FN, analogous to UPLC IGP5), and
B4GALT1 (p = 5.461028 for G2F, analogous to UPLC IGP13)
confirming GWAS signals in the discovery meta-analysis.

Replication of our findings

Investigating the biomarker potential of IgG N-glycans in
Systemic Lupus Erythematosus (SLE)

We then sought a separate independent replication of the other
14 genome-wide significant and strongly suggestive signals
identified in the discovery analysis, which was performed in the
LLS cohort, appreciating that the quantitated N-glycan traits do
not exactly match between the two cohorts. SNPs were chosen for
replication based on initial meta-analysis results of genotype data
prior to imputed analysis. All five traits measured in LLS cohort
were tested for association with all the selected SNPs (Table S6).
We were able to reproduce association to ST6GAL1 (p = 8.161027
for G2F, substrate for sialyltransferase) and SMARCB1-DERL3
(p = 1.661027 for G1N, analogous to UPLC IGP9). Weaker,
though nominally significant associations were confirmed at IKZF1
(p = 2.361023 for G1N), SLC38A10 (p = 4.861023 for G2N),
IL6ST-ANKRD55 (p = 1.361022 for G0N) and ABCF2-SMARCD3
(p = 2.761022 for G2N). The fact that we did not replicate
associations at the other 8 loci was not unexpected, because those
8 loci showed association with UPLC-measured N-glycan traits
that do not compare to any of the traits measured by MS (see
Table S5 for comparison of MS and UPLC traits).

Given that IKZF1 has been convincingly associated with SLE in
previous studies [35–37], and that functional studies in heterozygous knock-out mice in our study showed clear differences in
profiles of several IgG N-glycan traits, we explored an intriguing
hypothesis: whether the same IgG N-glycan traits that were
significantly affected in Ikzf1 knock-out mice could be demonstrated to differ between human SLE cases and controls. If this
were true, then pleiotropy between the effects of IKZF1 on SLE
and on IgG N-glycans in human plasma, revealed by independent
GWA studies, would lead to a discovery of a novel class of
biomarkers of SLE – IgG N-glycans – which could possibly extend
their usefulness in prediction of other autoimmune disorders,
cancer and neuropsychiatric disorders, through the same mechanism.
To test this hypothesis, we measured IgG N-glycans in 101 SLE
cases and 183 matched controls (typically two controls per case),
recruited in Trinidad (see materials and methods for further
details). Table 4 shows the results of the measurements: for 10 of
12 N-glycan traits chosen on a basis of the experiments in mice
(Table 3). The entire dataset for all glycans can be found in Table
S8. There was a statistically significant difference (p,0.05)
between SLE cases and controls, which was generally not the
case with other groups of N-glycans (data not shown). Moreover,

Functional experiment: Ikzf1 haplodeficiency results in
altered N-glycosylation of IgG
IKZF1 is considered to be the important regulator governing
differentiation of T cells into CD4+ and CD8+ T cells [67].
PLOS Genetics | www.plosgenetics.org
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Table 3. Twelve groups of IgG N-glycans (of 77 measured) that showed nominally significant difference (p,0.05) in observed
values between 5 mice that were heterozygous Ikzf1 knock-outs (Neo) and 5 wild-type controls (wt).

Increased N-glycans
N-glycan group code

N-glycan trait

Mean (Neo)

Mean (wt)

Mean(Neo)/Mean(wt)

p-value*

IGP8

GP9 - FA2[3]G1

8.91

7.44

1.20

3.54E-03

IGP48

GP9n – GP9/GPn*100

11.71

10.34

1.13

1.41E-02

IGP64

% FG1n/G1n

98.47

97.53

1.01

2.63E-02

Decreased N-glycans
N-glycan group code

N-glycan trait

Mean (Neo)

Mean (wt)

Mean(Neo)/Mean(wt)

p-value*

IGP9

GP10 - FA2[6]BG1

0.13

0.17

0.76

2.32E-03

IGP10

GP11 - FA2[3]BG1

0.34

0.62

0.55

4.74E-02

IGP19

GP20 – (undetermined)

12.29

15.07

0.82

7.62E-03

IGP23

GP24 - FA2BG2S2

1.27

1.50

0.85

3.20E-02

IGP37

FBS1/FS1

0.12

0.18

0.67

4.93E-02

IGP38

FBS1/(FS1+FBS1)

0.10

0.15

0.67

4.84E-02

IGP49

GP10n – GP10/GPn*100

0.17

0.24

0.71

1.71E-03

IGP50

GP11n – GP11/GPn*100

0.44

0.87

0.51

4.27E-02

IGP68

% FBG1n/G1n

1.15

2.05

0.56

2.76E-02

The global difference test was significant (p = 0.03). *t-test for equality of means (2-tailed).
doi:10.1371/journal.pgen.1003225.t003

To strengthen our findings and control for possible bias, we
repeated the analysis excluding all the cases on corticosteroid
treatment at the time of interview (77/101) and subsequently all
the cases that were not on corticosteroid treatment at the time of
interview (24/101). Although the power of the analysis decreased
due to reduced number of cases, the results did not change and
they remained highly statistically significant. We also hypothesized
that the observed glycan changes may not be specific to SLE, but

the significance of the difference was striking in some cases, e.g.
p,10214 for IGP48, p,10213 for IGP8, and p,1026 for IGP64.
Furthermore, the differences in the direction of effect in mice were
strikingly preserved in humans (Table 4). The most significant
differences observed across all 77 IgG N-glycans measurements
between SLE cases and controls (Table 4) were overlapping well
with the 12 N-glycan groups that were significantly changed in
functional experiments in Ikzf1 knock-out mice.

Table 4. Groups of IgG N-glycans from Table 3 that showed statistically significant difference in observed values (corrected by sex,
age, and African admixture) between 101 Afro-Caribbean cases with SLE and 183 controls.

Decreased N-glycans
N-glycan group code

N-glycan trait

Mean (SLE)

Mean (controls)

Mean(SLE)/Mean(controls)

p-value*

IGP8

GP9 - FA2[3]G1

6.67

8.03

0.83

1.86E-14

IGP48

GP9n – GP9/GPn*100

9.09

11.06

0.82

6.72E-15

IGP64

% FG1n/G1n

80.93

83.22

0.97

5.07E-07

IGP19

GP20 – (undetermined)

0.73

0.80

0.91

4.87E-02

N-glycan group code

N-glycan trait

Mean (SLE)

Mean (controls)

Mean(SLE)/Mean(controls)

p-value*

IGP9

GP10 - FA2[6]BG1

4.58

4.13

1.10

4.37E-04

IGP23

GP24 - FA2BG2S2

3.00

2.65

1.13

1.67E-03

IGP37

FBS1/FS1

0.20

0.18

1.11

5.08E-03

IGP38

FBS1/(FS1+FBS1)

0.17

0.15

1.13

4.83E-03

IGP49

GP10n – GP10/GPn*100

6.24

5.70

1.09

1.39E-03

IGP68

% FBG1n/G1n

17.34

15.30

1.13

2.19E-06

Increased N-glycans

*t-test for equality of means (2-tailed).
doi:10.1371/journal.pgen.1003225.t004
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and no training, which suggests that the predictive power of IGP48
on SLE is very robust.

may be caused by corticosteroid treatment, or secondary to any
inflammatory process. For this reason, and in SLE cases only, we
investigated whether corticosteroid treatments and/or CRP
measurements, were associated with IgG N-glycan traits. Analysis
for CRP was repeated with CRP treated as a binary variable (with
cut-off value at 10 mg/L). In all these analyses, the initial results
held and were not changed: the association of IgG N-glycans and
SLE remained striking, while the association with corticosteroid
treatment and CRP was not (Table S9). Finally, we also repeated
the analysis adjusting for percent African admixture, as it has been
reported that SLE in Afro-Caribbean population is associated with
African admixture [69]. However, this adjustment only had a
minor and non-systemic effect on the previous results, and the
reported observations remained.
We then validated biomarker potential of IGP48, the IgG Nglycan trait most significantly associated with SLE status, in
prediction of SLE in 101cases and 183 matched controls. We used
the PredictABEL package for R (see materials and methods) [70].
As shown in Figure 3, age, sex and African admixture did not have
any predictive power for this disease, but addition of IGP48
substantially increased sensitivity and specificity of prediction, with
area under receiver-operator curve (AUC) increasing from 0.515
(95% confidence interval (CI): 0.441–0.590) to 0.842 (0.791–
0.893). It is likely that further additions of other IgG N-glycans
could provide even more accurate predictions. To cross-validate
this result, we split our dataset with SLE cases and controls into a
‘‘training set’’ (2/3; 67 cases and 122 controls) and ‘‘test set’’ (1/3;
34 cases and 61 controls). Area under ROC-curve (AUC) was
calculated for the test dataset. The whole process was repeated
1000 times, to allow computation of the mean AUC (and 95% CI)
in the test datasets. Mean AUC was virtually unchanged
compared to AUC obtained when using the complete dataset

Discussion
This study clearly demonstrates that the recent developments in
high-throughput glycomics and genomics now allow identification
of genetic loci that control N-glycosylation of a single plasma
protein using a GWAS approach. This progress should allow
many similar follow-up studies of genetic regulation of Nglycosylation of other important plasma proteins, thus bringing
unprecedented insights into the role of protein glycosylation in
systems biology. As a prelude to this discovery, we recently
reported the results of the first GWA study of the overall human
plasma N-glycome using the HPLC method. Although the study
was of a comparable sample size (N,2000), it only identified
genome-wide associations with two glycosyltransferases and one
transcription factor (HNF1a) [71]. We believe that the power of
our initial study was reduced because N-glycans in human plasma
originate from different glycoproteins where they have different
functions and undergo protein-specific, or tissue-specific glycosylation. In this study the largest percentage of variance explained by
a single association was 16–18% where as in the N-glycan study
this was 1–6%. Furthermore, concentrations of individual
glycoproteins in plasma vary in many physiological processes,
introducing substantial ‘‘noise’’ to the quantitation of the wholeplasma N-glycome.
In this study we avoided both problems by isolating a single
protein from plasma (IgG), which is produced by a single cell type
(B lymphocytes), thus effectively excluding differential regulation
of gene expression in different tissues, and the ‘‘noise’’ introduced
by variation in plasma IgG concentration and by N-glycans on
other plasma proteins. The only remaining ‘‘noise’’ in our system
was the incomplete separation of some glycan structures (which coeluted from the UPLC column) and the presence of Fab glycans on
a subset of IgG molecules, but for the majority of glycan structures
this ‘‘noise’’ was well below 10% [19]. We expected that the
specificity of our phenotype and precision of the measurement
provided by novel UPLC and MS methods should substantially
increase the power of the study to detect genome-wide associations. Prior to analysis we could not predict which quantitation
method would work better in GWA study design (UPLC vs. MS),
so we used them both, each in one separate cohort of comparable
sample size (N,2000).
The UPLC method yielded many more, and much stronger,
genome-wide association signals in comparison to our previous
study of the total plasma N-glycome in virtually same sample set of
examinees [27,71]. Sixteen loci were identified in association with
glycan traits with p-values,561028 and nine reached the strict
genome wide threshold of 2.2761029. The parallel study in the
LLS cohort using MS quantitation has independently identified
two of those 16 loci, showing genome-wide association with Nglycan traits. MS quantitation also allowed us to replicate 6 further
loci identified in the discovery analysis, using comparable N-glycan
traits measured by the two methods. However, in this follow-up
analysis we were unable to replicate associations for the remaining
8 loci. This was not unexpected, because those glycosylation traits
correspond to different fucosylated glycans; since fucosylation was
not quantified by MS, the association between glycans measured
by MS and those regions should not be expected.
Among the nine loci that reached genome-wide statistical
significance, four involved genes encoding glycosyltransferases
known to glycosylate IgG (ST6GALI, B4GALT1, FUT8, MGAT3,).
The enzyme beta1,4-galactosyltransferase 1 is responsible for the

Figure 3. Validation of biomarker potential of IGP48 IgG Nglycan percentage in prediction of Systemic Lupus Erythematosus (SLE) in 101 Afro-Caribbean cases and 183 matched
controls. As shown in the graph, age and sex do not have any
predictive power for this disease, but addition of IGP48 substantially
increases sensitivity and specificity of prediction, with area under
receiver-operator curve increased to 0.828.
doi:10.1371/journal.pgen.1003225.g003

PLOS Genetics | www.plosgenetics.org

11

January 2013 | Volume 9 | Issue 1 | e1003225

Genetic Loci Affecting IgG Glycosylation

addition of galactose to IgG glycans. Interestingly, variants in
B4GALT1 gene did not affect the main measures of IgG
galactosylation, but rather differences in sialylation and the
percentage of bisecting GlcNAc. These associations are still
biologically plausible, because galactosylation is a prerequisite
for sialylation, and enzymes which add galactose and bisecting
GlcNAc compete for the same substrate [72]. A potential
candidate for B4GALT1 regulator is IL6ST, which codes for
interleukin 6 signal transducer, because it showed stronger
associations with the main measures of IgG galactosylation than
B4GALT1 itself. Molecular mechanisms behind this association
remain elusive, but early work on IL6 (then called PHGF)
suggested that it may be relevant for glycosylation pathways in B
lymphocytes [73].
Core-fucosylation of IgG has been intensively studied due to its
role in antibody-dependent cell-mediated cytotoxicity (ADCC).
This mechanism of killing is considered to be one of the major
mechanisms of antibody-based therapeutics against tumours.
Core-fucose is critically important in this process, because IgGs
without core fucose on the Fc glycan have been found to have
ADCC activity enhanced by up to 100-fold [74]. Alpha-(1,6)fucosyltransferase (fucosyltransferase 8) catalyses the transfer of
fucose from GDP-fucose to N-linked type complex glycopeptides,
and is encoded by the FUT8 gene. We found that SNPs located
near this gene influenced overall levels of fucosylation. The
directly measured IgG glycome traits most strongly associated with
SNPs in the FUT8 region consisted of A2, and, less strongly, A2G1
and A2G2. These associations are biologically plausible as these
glycans serve as substrates for fucosyltransferase 8. Interestingly,
SNPs located near the IKZF1 gene influenced fucosylation of a
specific subset of glycans, especially those without bisecting
GlcNAc, and were also related to the ratio of fucosylated
structures with and without bisecting GlcNAc. This suggests the
IKZF1 gene encoding Ikaros as a potential indirect regulator of
fucosylation in B-lymphocytes by promoting the addition of
bisecting GlcNAc, which then inhibits fucosylation. The analysis of
IgG glycosylation in Ikzf1 haplodeficient mice confirmed the
postulated role of Ikaros in the regulation of IgG glycosylation
(Table 3). The effect of Ikzf1 haplodeficiency on IgG glycans
manifested mainly in the decrease in bisecting GlcNAc on different
glycan structures. The increase in fucose was observed only in a
subset of structures, but since very high level of fucosylation was
present in the wild type mouse (up to 99.8%), a further increase
could not have been demonstrated.
Nearly all genome-wide significant loci in our study have
already been clearly demonstrated to be associated with autoimmune diseases, haematologic cancers, and some of them also with
chronic inflammation and/or neuropsychiatric disorders. Although the literature on those associations is extensive, we tried
to highlight only those associations that were identified using
genome-wide association studies in datasets independent from our
study. We gave prominence to associations arising from GWA
studies because they are typically replicable; GWA studies have
sufficient power to detect true associations, and require stringent
statistical testing and replication to avoid false positive results.
They have been reviewed and summarized in Table 2. The table
implies abundant pleiotropy between loci that control N-glycosylation (in this case, of IgG protein) and loci that have been
implicated in many human diseases. Autoimmune diseases
(including SLE, RA, UC and over 80 others) are generally
thought to be triggered by aggressive responses of the adaptive
immune system to self antigens, resulting in tissue damage and
pathological sequelae [38]. Among other mechanisms, IgG
autoantibodies are responsible for the chronic inflammation and
PLOS Genetics | www.plosgenetics.org

destruction of healthy tissues by cross-linking Fc receptors on
innate immune effector cells [75]. Class and glycosylation of IgG
are important for pathogenicity of autoantibodies in autoimmune
diseases (reviewed in [76]). Removal of IgG glycans leads to the
loss of the proinflammatory activity, suggesting that in vivo
modulation of antibody glycosylation might be a strategy to
interfere with autoimmune processes [75]. Indeed, the removal of
IgG glycans by injections of EndoS in vivo interfered with
autoantibody-mediated proinflammatory processes in a variety of
autoimmune models [75].
Results from our study suggest that IgG N-glycome composition
is regulated through a complex interplay between loci affecting an
overlapping spectrum of glycome measurements, and through
interaction of genes directly involved in glycosylation and those
that presumably have a ‘‘higher-level’’ regulatory function. SNPs
at several different loci in this GWA study showed genome-wide
significant associations with the same or similar IgG glycosylation
traits. For example, SNPs at loci on chromosomes 9 (B4GALT1
region) and 3 (ST6GAL1 region) both influenced the percentage of
sialylation of galactosylated fucosylated structures (without bisecting GlcNAc) in the same direction. SNPs at these loci also
influenced the ratio of fucosylated monosialylated structures (with
and without bisecting GlcNAc) in the opposite direction. SNPs at
the locus on chromosome 9 (B4GALT1), and two loci on
chromosome 22 (MGAT3 and SMARCB1-DERL3 region) simultaneously influenced the ratio of fucosylated disialylated structures
with and without bisecting GlcNAc. SNPs at loci on chromosome
7 (IKZF1 region) and 14 (FUT8 region) influenced an overlapping
range of traits: percentage of A2 and A2G1 glycans, and, in the
opposite direction, the percentage of fucosylation of agalactosylated structures.
Finally, this study demonstrated that findings from ‘‘hypothesisfree’’ GWA studies, when targeted at a well defined biological
phenotype of unknown relevance to human health and disease
(such as N-glycans of a single plasma protein), can implicate
genomic loci that were not thought to influence protein
glycosylation. Moreover, unexpected pleiotropy of the implicated
loci that linked them to diseases has changed this study from
‘‘hypothesis-free’’ to ‘‘hypothesis-driven’’ [77], and led us to
explore biomarker potential of a very specific IgG N-glycan trait in
prediction of a specific disease (SLE) with considerable success. To
our knowledge, this is one of the first convincing demonstrations
that GWA studies can lead to biomarker discovery for human
disease. This study offers many additional opportunities to validate
the role of further N-glycan biomarkers for other diseases
implicated through pleiotropy.

Conclusions
A new understanding of the genetic regulation of IgG N-glycan
synthesis is emerging from this study. Enzymes directly responsible
for the addition of galactose, fucose and bisecting GlcNAc may not
have primary responsibility for the final IgG N-glycan structures.
For all three processes, genes that are not directly involved in
glycosylation showed the most significant associations: IL6STANKRD55 for galactosylation; IKZF1 for fucosylation; and
SMARCB1-DERL3 for the addition of bisecting GlcNAc. The
suggested higher-level regulation is also apparent from the
differences in IgG Fab and Fc glycosylation, observed in human
IgG [78,79] and different myeloma cell lines [80], and further
supported by recent observation that various external factors
exhibit specific effects on glycosylation of IgG produced in
cultured B lymphocytes [81].
Moreover, this study showed that it is possible to identify loci
that control glycosylation of a single plasma protein using a
12
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peoples living in the north of Sweden [84]. Complete data were
available from 179 participants aged 14 to 91 years.
DNA samples were genotyped according to the manufacturer’s
instructions on Illumina Infinium SNP bead microarrays (HumanHap300v1 for CROATIA-Vis, HumanHap300v2 for ORCADES and NSPHS and HumanCNV370v1 for CROATIAKorcula). Genotypes were determined using Illumina BeadStudio
software. Genotyping was successfully completed on 991 individuals from CROATIA-Vis, 953 from CROATIA-Korcula, 889
from ORCADES and 700 from NSPHS, providing a platform for
genome-wide association study of multiple quantitative traits in
these founder populations.
The Leiden Longevity Study (LLS) has been described in detail
previously [85]. It is a family based study and consists of 1671
offspring of 421 nonagenarian sibling pairs of Dutch descent, and
their 744 partners. 1848 individuals with available genotypic and
IgG measurements data were included in the current analysis.
Within the Leiden Longevity Study 1345 individuals were
genotyped using Illumina660 W (Rotterdam, Netherlands) and
503 individuals were genotyped using Illumina OmniExpress
(Estonian Biocentre, Genotyping Core Facility, Estonia).

GWAS approach, and to develop a novel class of disease
biomarkers. This should lead to large advances in understanding
of the role of protein glycosylation in the future. This study
identified 16 genetic loci that are likely to be part of a much larger
genetic network that regulates the complex process of IgG Nglycosylation and several further loci that show suggestive
association with glycan traits and merit further study. Genetic
variants in several of these genes were previously associated with a
number of inflammatory, neoplastic and neuropsychiatric diseases
across ethnically diverse populations, all of which could benefit
from earlier and more accurate diagnosis based on molecular
biomarkers. Variations in individual SNPs have relatively small
effects, but when several polymorphisms are combined in a
complex pathway like N-glycosylation, the final product of the
pathway - in this case IgG N-glycan - can be significantly different,
with consequences for IgG function and possibly also disease
susceptibility. Our results may also provide an explanation for the
reported pleiotropy and antagonistic genetic effects of loci involved
in autoimmune diseases and hematologic cancers [39,77].

Materials and Methods

Isolation of IgG and glycan analysis

Ethics statement

In the discovery population cohorts (CROATIA-Vis, CROATIA-Korcula, ORCADES, and NSPHS), the IgG was isolated
using protein G plates and its glycans analysed by UPLC in 2247
individuals, as reported previously [19]. Briefly, IgG glycans were
labelled with 2-AB fluorescent dye and separated by hydrophilic
interaction ultra-performance liquid chromatography (UPLC).
Glycans were separated into 24 chromatographic peaks and
quantified as relative contributions of individual peaks to the total
IgG glycome. The majority of peaks contained individual glycan
structures, while some contained more structures. Relative
intensities of each glycan structure in each UPLC peak were
determined by mass spectrometry as reported previously [19]. On
the basis of these 24 directly measured ‘‘glycan traits’’, additional
54 ‘‘derived traits’’ were calculated. These include the percentage
of galactosylation, fucosylation, sialylation, etc. described in the
Table S1. When UPLC peaks containing multiple traits were used
to calculate derived traits, only glycans with major contribution to
fluorescence intensity were used.
In the replication population cohort (Leiden Longevity Study),
the IgG was isolated from plasma samples of 1848 participants.
Glycosylation patterns of IgG1 and IgG2 were investigated by
analysis of tryptic glycopeptides using MALDI-TOF MS. Six
glycoforms per IgG subclass were determined by MALDITOFMS. Since the intensities of all glycoforms were related to
the monogalactosylated, core-fucosylated biantennary species
(glycoform B), five relative intensities were registered per IgG
subclass [86].

All research in this study that involved human participants has
been approved by the appropriate ethics committees: the Ethics
Committee of the University of Split Medical School for all
Croatian examinees from Vis and Korcula islands; the Local
Research Ethics Committees in Orkney and Aberdeen for the
Orkney Complex Disease Study (ORCADES); the University of
Uppsala (Dnr 2005:325) for all examinees from Northern Sweden;
the Leiden University Medical Centre Ethical Committee for all
participants in the Leiden Longevity Study (LLS); and the Ethics
Committee of the London School of Hygiene and Tropical
Medicine for all SLE cases and controls from Trinidad. All ethics
approvals were given in compliance with the Declaration of
Helsinki (World Medical Association, 2000). All human subjects
included in this study have signed appropriate informed consent.

Study participants—discovery and replication cohorts
All population studies recruited adult individuals within a
community irrespective of any specific phenotype. Fasting blood
samples were collected, biochemical and physiological measurements taken and questionnaire data for medical history as well as
lifestyle and environmental exposures were collected following
similar protocols. Basic cohort descriptives are included in Table
S11.
The CROATIA-Vis study includes 1008 Croatians, aged 18–93
years, who were recruited from the villages of Vis and Komiža on
the Dalmatian island of Vis during 2003 and 2004 within a larger
genetic epidemiology program [82]. The CROATIA-Korcula
study includes 969 Croatians between the ages of 18 and 98 [83].
The field work was performed in 2007 and 2008 in the eastern
part of the island, targeting healthy volunteers from the town of
Korčula and the villages of Lumbarda, Žrnovo and Račišće.
The Orkney Complex Disease Study (ORCADES) was
performed in the Scottish archipelago of Orkney and collected
data between 2005 and 2011 [84]. Data for 889 participants aged
18 to 100 years from a subgroup of ten islands, were used for this
analysis.
The Northern Swedish Population Health Study (NSPHS) is a
family-based population study including a comprehensive health
investigation and collection of data on family structure, lifestyle,
diet, medical history and samples for laboratory analyses from
PLOS Genetics | www.plosgenetics.org

Genotype and phenotype quality control
Genotyping quality control was performed using the same
procedures for all four discovery populations (CROATIA-Vis,
CROATIA-Korcula, ORCADES, and NSPHS). Individuals with
a call rate less than 97% were removed as well as SNPs with a call
rate less than 98% (95% for CROATIA-Vis), minor allele
frequency less than 0.02 or Hardy-Weinberg equilibrium p-value
less than 1610210. 924 individuals passed all quality control
thresholds from CROATIA-Vis, 898 from CROATIA-Korcula,
889 from ORCADES and 656 from NSPHS.
Extreme outliers (those with values more than 3 times the
interquartile distances away from either the 75th or the 25th
percentile values) were removed for each glycan measure to
13
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percentage of the variance explained was calculated for each glycan
trait adjusted for sex, age and first 3 principal components in each
cohort individually using the ‘‘polygenic’’ function of the GenABEL
package for R. Conditional analysis was undertaken for all
significant and suggestive regions. GWAS was performed as
described above with the additional adjustment for the dosage of
the top SNP in the region for only the chromosome containing the
association. Subsequent meta-analysis was performed as described
previously and the results visualised using LocusZoom to ensure that
the association peak have been removed.
In LLS, all IgG measurements were log-transformed. The score
statistic for testing for an additive effect of a diallelic locus on
quantitative phenotype was used. To account for relatedness in
offspring data we used the kinship coefficients matrix when
computing the variance of the score statistic. Imputation was dealt
with by accounting for loss of information due to genotype
uncertainty [90]. For the association analysis of the GWAS data,
we applied the score test for the quantitative trait correcting for sex
and age using an executable C++ program QTassoc (http://www.
lumc.nl/uh, under GWAS Software). For further details we refer
to supplementary online information.

account for errors in quantification and to remove individuals not
representative of normal variation within the population. After
phenotype quality control the number of individuals with complete
phenotype and covariate information for the meta-analysis was
2247, consisting of 906 men and 1341 women (802 from
CROATIA-Vis, 851 from CROATIA-Korcula, 415 from ORCADES, 179 from NSPHS).
In Leiden Longevity Study, GenomeStudio was used for
genotyping calling algorithm. Sample call rate was .95%, and
SNP exclusions criteria were Hardy-Weinberg equilibrium p
value,1024, SNP call rate,95%, and minor allele frequency
,1%. The number of the overlapping SNPs that passed quality
controls in both samples was 296,619.
To combine the data from the different array sets and to
increase the overall coverage of the genome to up to 2.5 million
SNPs, we imputed autosomal SNPs reported in the Haplotype
Mapping Project (release #22, http://hapmap.ncbi.nlm.nih.gov)
CEU sample. Based on the SNPs that were genotyped in all arrays
and passed quality control, the imputation programmes MACH
(http://www.sph.umich.edu/csg/abecasis/MACH/) or IMPUTE2 (http://mathgen.stats.ox.ac.uk/impute/impute_v2.html)
were used to obtain ca. 2.5 million SNPs for further analysis.
For replication of genome-wide significant hits identified in the
discovery meta-analysis, all SNPs listed in Table S6 were used and
looked up in LLS. The only exception was rs11621121, which had
low imputation accuracy and did not pass quality control criteria.
For this SNP, a set of 11 proxy SNPs from HapMap r. 22 (all with
R2.0.85) was studied. All studied SNPs had imputation quality of
0.3 or greater.

Experiments in Ikzf1 knockout mice
The Ikzf1+/2 mice harbouring the Neo-PAX5-IRES-GFP knock
in allele were obtained from Meinrad Busslinger (IMP, Vienna) and
backcrossed to C57BL/6 mice. Both wild-type and Ikzf1Neo+/2
animals at the age of about 8 months were subjected to retro-orbital
puncture to collect blood in the presence of EDTA. Samples were
centrifuged for 10 minutes at room temperature and plasma was
harvested. IgG was isolated and subjected to glycan analyses.
Statistical significance of the difference in distributions of IgG
glycome between wild type and the Ikzf1+/2 mice was assessed
using empirical version of the Hotelling’s test. In brief, the
empirical distribution of the Hotelling’s T2 statistics was worked
out by permuting the group status of the animals at random
without replacement 10,000 times. This empirical distribution was
then contrasted with the original value of T2, with the proportion
of empirically observed T2 values greater than or equal to the
original T2 regarded as the empirical p-value.

Genome-wide association analysis
In the discovery populations, genome-wide association analysis
was firstly performed for each population and then combined using
an inverse-variance weighted meta-analysis for all traits. Each trait
was adjusted for sex, age and the first 3 principal components
obtained from the population-specific identity-by-state (IBS) derived
distances matrix. The residuals were transformed to ensure their
normal distribution using quantile normalisation. Sex-specific
analyses were adjusted for age and principal components only.
The residuals expressed as z-scores were used for association
analysis. The ‘‘mmscore’’ function of ProbABEL [87] was used for
the association test under an additive model. This score test for
family based association takes into account relationship structure and
allowed unbiased estimations of SNP allelic effect when relatedness is
present between examinees. The relationship matrix used in this
analysis was generated by the ‘‘ibs’’ function of GenABEL (using
weight = ‘‘freq’’ option), which uses genomic data to estimate the
realized pair-wise kinship coefficient. All lambda values for the
population-specific analyses were below 1.05 (Table S4), showing
that this method efficiently accounts for family structure.
Inverse-variance weighted meta-analysis was performed using the
MetABEL package (http://www.genabel.org) for R. SNPs with
poor imputation quality (R2,0.3) were excluded prior to metaanalysis. Principal component analysis was performed using R to
determine the number of independent traits used for these analyses
(Table S10). 21 principal components explained 99% of the
variance so an association was considered statistically significant at
the genome-wide level if the p-value for an individual SNP was less
than 2.2761029 (561028/22 traits) [88]. SNPs were considered
strongly suggestive with p-values between 561028 and 2.2761029.
Regions of association were visualized using the web-based software
LocusZoom [89] to display the linkage disequilibrium (LD) of the
region based on hg18/1000 Genomes June 1010 CEU data. The
effect of the most significant SNP in each gene region expressed as
PLOS Genetics | www.plosgenetics.org

Dataset with SLE cases and matched controls
A total of 101 SLE cases and 183 controls from Trinidad were
studied. The inclusion criteria for cases and controls in Trinidad
were designed to restrict the sample to individuals without Indian
or Chinese ancestry. Cases and controls were eligible to be
included if they were resident in northern Trinidad (excluding the
southern part of the island where Indians are in the majority) and
they had Christian (rather than Hindu, Muslim or Chinese) first
names. Identification of cases was carried out by contacting all
physicians specializing in rheumatology, nephrology and dermatology at the two main public hospitals in northern Trinidad and
asking for a list of all SLE patients from their out-patient clinics. At
the main dermatology clinic a register of cases since 1992 was
available. Furthermore, a systematic search of: (a) outpatient
records at the two hospitals, (b) hospital laboratory test results
positive for auto-antibodies (anti-nuclear or anti-double-stranded
DNA antibody titre .1:256) and (c) histological reports of skin
biopsy examination consistent with SLE was performed. Lastly,
SLE cases were also identified through the Lupus Society of
Trinidad and Tobago (90% of those patients were also identified
through one of the two main public hospitals). For each case,
randomly chosen households in the same neighbourhood were
sampled by the field team to obtain (where possible) two controls,
matched with the case for sex and for 20-year age group. Cases
14
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Table S5 Description of five glycan traits measured by MS and
their descriptive statistic in the replication cohort.
(XLS)

and controls were interviewed at home or in the project office by
using a custom made questionnaire.
The case definition of SLE was based on American Rheumatism Association (ARA) criteria [91], applied to medical records
(available for more than 90% of cases), and to the medical history
given by the patient. Informed consent for blood sampling and the
use of the sample for genetic studies including estimation of
admixture was obtained from each participant. Initial case
ascertainment identified 264 possible cases of SLE. Of these, 72
(27%) were excluded either on the basis of their names or because
their medical history did not meet ARA criteria for the diagnosis of
SLE. Of the remaining 192 individuals, 54 had incomplete
addresses or were not resident in northern Trinidad, four were too
ill to be interviewed, eight were aged less than 18 years and two
refused to participate. For 80% (99/124) of cases, two matched
controls were obtained: the response rate from those invited to
participate as controls was 70%. The total sample consisted of 124
cases and 219 controls aged over 20 years who completed the
questionnaire. Blood samples were obtained from 122 cases and
219 controls and DNA was successfully extracted from 93% (317/
341) of these. IgG glycans were successfully measured in 303
individuals. Age at sampling was not available for 17 individuals
and 2 individuals were lost due to the ID mismatch.
To test predictive power of selected glycan trait, we fitted
logistic regression models (including and excluding the glycan) and
used predRisk function of PredictABEL package for R to evaluate
the predictive ability.

Table S6 Summary data for all single-nucleotide polymorphisms

with replicated in the LLS cohort.
(XLS)
Table S7 IgG glycans in 5 heterozygous Ikzf1 knockout mice
and 5 wild-type controls.
(XLS)
Table S8 Data for all IgG N-glycans measured in 101 AfroCaribbean cases with SLE and 183 controls (Extended Table 4
from the main manuscript).
(XLS)
Table S9 Effects of corticosteroids on IgG glycans.

(XLS)
Table S10

Principal component analysis of IgG glycosylation

traits.
(XLS)
Table S11

Description of the analysed populations.

(XLS)

Acknowledgments
The CROATIA-Vis and CROATIA-Korcula studies would like to
acknowledge the invaluable contributions of the recruitment team
(including those from the Institute of Anthropological Research in Zagreb)
in Vis and Korcula, the administrative teams in Croatia and Edinburgh,
and the people of Vis and Korcula. ORCADES would like to acknowledge
the invaluable contributions of Lorraine Anderson, the research nurses in
Orkney, and the administrative team in Edinburgh. SNP genotyping of the
CROATIA-Vis samples and DNA extraction for ORCADES was carried
out by the Genetics Core Laboratory at the Wellcome Trust Clinical
Research Facility, WGH, Edinburgh, Scotland. SNP genotyping for
CROATIA-Korcula and ORCADES was performed by Helmholtz
Zentrum München, GmbH, Neuherberg, Germany. The authors are
grateful to all patients and staff who contributed to the collection in
Trinidad and the UK.

Supporting Information
Figure S1 Forrest plots for associations of glycan traits measured

by UPLC and genetic polymorphisms.
(PPT)
Table S1 The description of 23 quantitative IgG glycosylation
traits measured by UPLC and 54 derived traits.
(XLS)
Table S2 Descriptive statistics of glycan traits in discovery

cohorts.
(XLS)

Author Contributions

Summary data for all single-nucleotide polymorphisms
and traits with suggestive associations (p,1610-5) with glycans
measured by UPLC.
(XLS)
Table S3

Conceived and designed the experiments: GL MW AFW PMR CH YA
HC IR. Performed the experiments: JEH MP BA AM MN JK TK BS
LRR. Analyzed the data: LZ OP OG VV H-WU MM OS JJH-D PES MB
YA. Contributed reagents/materials/analysis tools: ALP PM IK IKL
FNvL AJMdC AMD QZ WW NDH UG JFW PMR. Wrote the paper: GL
IR.

Table S4 Population-specific and pooled genomic control (GC)

factors for associations with UPLC glycan traits.
(XLS)

References
8. Sutton BJ, Phillips DC (1983) The three-dimensional structure of the
carbohydrate within the Fc fragment of immunoglobulin G. Biochem Soc
Trans 11: 130–132.
9. Harada H, Kamei M, Tokumoto Y, Yui S, Koyama F, et al. (1987) Systematic
fractionation of oligosaccharides of human immunoglobulin G by serial affinity
chromatography on immobilized lectin columns. Anal Biochem 164: 374–381.
10. Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, et al. (1985)
Association of rheumatoid arthritis and primary osteoarthritis with changes in
the glycosylation pattern of total serum IgG. Nature 316: 452–457.
11. Kaneko Y, Nimmerjahn F, Ravetch JV (2006) Anti-inflammatory activity of
immunoglobulin G resulting from Fc sialylation. Science 313: 670–673.
12. Anthony RM, Ravetch JV (2010) A novel role for the IgG Fc glycan: the antiinflammatory activity of sialylated IgG Fcs. J Clin Immunol 30 Suppl 1: S9–14.
13. Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune
responses. Nat Rev Immunol 8: 34–47.
14. Ferrara C, Stuart F, Sondermann P, Brunker P, Umana P (2006) The
carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity
binding to non-fucosylated IgG glycoforms. J Biol Chem 281: 5032–5036.

1. Opdenakker G, Rudd PM, Ponting CP, Dwek RA (1993) Concepts and
principles of glycobiology. FASEB Journal 7: 1330–1337.
2. Skropeta D (2009) The effect of individual N-glycans on enzyme activity. Bioorg.
Med.Chem. 17: 2645–2653.
3. Marek KW, Vijay IK, Marth JD (1999) A recessive deletion in the GlcNAc-1phosphotransferase gene results in peri-implantation embryonic lethality.
Glycobiology 9: 1263–1271.
4. Jaeken J, Matthijs G (2007) Congenital disorders of glycosylation: a
rapidly expanding disease family. Annu Rev Genomics Hum Genet 8:
261–278.
5. Kobata A (2008) The N-linked sugar chains of human immunoglobulin G: their
unique pattern, and their functional roles. Biochim Biophys Acta 1780: 472–478.
6. Jefferis R (2005) Glycosylation of recombinant antibody therapeutics. Biotechnol
Prog 21: 11–16.
7. Zhu D, Ottensmeier CH, Du MQ, McCarthy H, Stevenson FK (2003)
Incidence of potential glycosylation sites in immunoglobulin variable regions
distinguishes between subsets of Burkitt’s lymphoma and mucosa-associated
lymphoid tissue lymphoma. Br J Haematol 120: 217–222.

PLOS Genetics | www.plosgenetics.org

15

January 2013 | Volume 9 | Issue 1 | e1003225

Genetic Loci Affecting IgG Glycosylation

15. Mizushima T, Yagi H, Takemoto E, Shibata-Koyama M, Isoda Y, et al. (2011)
Structural basis for improved efficacy of therapeutic antibodies on defucosylation
of their Fc glycans. Genes to Cells 16: 1071–1080.
16. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, et al. (2003)
The absence of fucose but not the presence of galactose or bisecting Nacetylglucosamine of human IgG1 complex-type oligosaccharides shows the
critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem
278: 3466–3473.
17. Iida S, Misaka H, Inoue M, Shibata M, Nakano R, et al. (2006) Nonfucosylated
therapeutic IgG1 antibody can evade the inhibitory effect of serum
immunoglobulin G on antibody-dependent cellular cytotoxicity through its high
binding to FcgammaRIIIa. Clin Cancer Res 12: 2879–2887.
18. Preithner S, Elm S, Lippold S, Locher M, Wolf A, et al. (2006) High
concentrations of therapeutic IgG1 antibodies are needed to compensate for
inhibition of antibody-dependent cellular cytotoxicity by excess endogenous
immunoglobulin G. Mol Immunol 43: 1183–1193.
19. Pucic M, Knezevic A, Vidic J, Adamczyk B, Novokmet M, et al. (2011) High
throughput isolation and glycosylation analysis of IgG-variability and heritability
of the IgG glycome in three isolated human populations. Mol Cell Proteomics
10: M111 010090.
20. Kooner JS, Saleheen D, Sim X, Sehmi J, Zhang W, et al. (2011) Genome-wide
association study in individuals of South Asian ancestry identifies six new type 2
diabetes susceptibility loci. Nat Genet 43: 984–989.
21. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, et al. (2010)
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s
disease susceptibility loci. Nat Genet 42: 1118–1125.
22. Mells GF, Floyd JA, Morley KI, Cordell HJ, Franklin CS, et al. (2011) Genomewide association study identifies 12 new susceptibility loci for primary biliary
cirrhosis. Nat Genet 43: 329–332.
23. Aouizerat BE, Vittinghoff E, Musone SL, Pawlikowska L, Kwok PY, et al. (2011)
GWAS for discovery and replication of genetic loci associated with sudden
cardiac arrest in patients with coronary artery disease. BMC Cardiovasc Disord
11: 29.
24. Baranzini SE, Srinivasan R, Khankhanian P, Okuda DT, Nelson SJ, et al. (2010)
Genetic variation influences glutamate concentrations in brains of patients with
multiple sclerosis. Brain 133: 2603–2611.
25. Dick DM, Aliev F, Krueger RF, Edwards A, Agrawal A, et al. (2011) Genomewide association study of conduct disorder symptomatology. Mol Psychiatry 16:
800–808.
26. Pivac N, Knezevic A, Gornik O, Pucic M, Igl W, et al. (2011) Human plasma
glycome in attention-deficit hyperactivity disorder and autism spectrum
disorders. Mol Cell Proteomics 10: M110 004200.
27. Huffman JE, Knezevic A, Vitart V, Kattla J, Adamczyk B, et al. (2011)
Polymorphisms in B3GAT1, SLC9A9 and MGAT5 are associated with
variation within the human plasma N-glycome of 3533 European adults.
Hum Mol Genet 20: 5000–5011.
28. Oda Y, Okada T, Yoshida H, Kaufman RJ, Nagata K, et al. (2006) Derlin-2 and
Derlin-3 are regulated by the mammalian unfolded protein response and are
required for ER-associated degradation. J Cell Biol 172: 383–393.
29. Pottier N, Cheok MH, Yang W, Assem M, Tracey L, et al. (2007) Expression of
SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells:
identification of a promoter SNP that alters PARP1 binding and SMARCB1
expression. Hum Mol Genet 16: 2261–2271.
30. Chambers JC, Zhang W, Sehmi J, Li X, Wass MN, et al. (2011) Genome-wide
association study identifies loci influencing concentrations of liver enzymes in
plasma. Nat Genet 43: 1131–1138.
31. Sellars M, Reina-San-Martin B, Kastner P, Chan S (2009) Ikaros controls
isotype selection during immunoglobulin class switch recombination. J Exp Med
206: 1073–1087.
32. Klug CA, Morrison SJ, Masek M, Hahm K, Smale ST, et al. (1998)
Hematopoietic stem cells and lymphoid progenitors express different Ikaros
isoforms, and Ikaros is localized to heterochromatin in immature lymphocytes.
Proc Natl Acad Sci U S A 95: 657–662.
33. Trevino LR, Yang W, French D, Hunger SP, Carroll WL, et al. (2009) Germline
genomic variants associated with childhood acute lymphoblastic leukemia. Nat
Genet 41: 1001–1005.
34. Papaemmanuil E, Hosking FJ, Vijayakrishnan J, Price A, Olver B, et al. (2009)
Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute
lymphoblastic leukemia. Nat Genet 41: 1006–1010.
35. Cunninghame Graham DS, Morris DL, Bhangale TR, Criswell LA, Syvanen
AC, et al. (2011) Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with
Systemic Lupus Erythematosus. PLoS Genet 7: e1002341. doi:10.1371/
journal.pgen.1002341
36. Han JW, Zheng HF, Cui Y, Sun LD, Ye DQ, et al. (2009) Genome-wide
association study in a Chinese Han population identifies nine new susceptibility
loci for systemic lupus erythematosus. Nat Genet 41: 1234–1237.
37. Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, et al. (2009) A largescale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and
IL10 as risk loci for systemic lupus erythematosus. Nat Genet 41: 1228–1233.
38. Davidson A, Diamond B (2001) Autoimmune diseases. N Engl J Med 345: 340–
350.
39. Swafford AD, Howson JM, Davison LJ, Wallace C, Smyth DJ, et al. (2011) An
allele of IKZF1 (Ikaros) conferring susceptibility to childhood acute lymphoblastic leukemia protects against type 1 diabetes. Diabetes 60: 1041–1044.

PLOS Genetics | www.plosgenetics.org

40. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, et al. (2008) Genomewide association defines more than 30 distinct susceptibility loci for Crohn’s
disease. Nat Genet 40: 955–962.
41. Gorlova O, Martin JE, Rueda B, Koeleman BP, Ying J, et al. (2011)
Identification of novel genetic markers associated with clinical phenotypes of
systemic sclerosis through a genome-wide association strategy. PLoS Genet 7:
e1002178. doi:10.1371/journal.pgen.1002178
42. Jallow M, Teo YY, Small KS, Rockett KA, Deloukas P, et al. (2009) Genomewide and fine-resolution association analysis of malaria in West Africa. Nat
Genet 41: 657–665.
43. Ganesh SK, Zakai NA, van Rooij FJ, Soranzo N, Smith AV, et al. (2009)
Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium.
Nat Genet 41: 1191–1198.
44. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, et al. (2010) Genomewide association study meta-analysis identifies seven new rheumatoid arthritis
risk loci. Nat Genet 42: 508–514.
45. Gottardo L, De Cosmo S, Zhang YY, Powers C, Prudente S, et al. (2008) A
polymorphism at the IL6ST (gp130) locus is associated with traits of the
metabolic syndrome. Obesity (Silver Spring) 16: 205–210.
46. Birmann BM, Tamimi RM, Giovannucci E, Rosner B, Hunter DJ, et al. (2009)
Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of
multiple myeloma. Cancer Epidemiol Biomarkers Prev 18: 282–288.
47. Barrett JC, Lee JC, Lees CW, Prescott NJ, Anderson CA, et al. (2009) Genomewide association study of ulcerative colitis identifies three new susceptibility loci,
including the HNF4A region. Nat. Genet. 41: 1330–1334.
48. Silverberg MS, Cho JH, Rioux JD, McGovern DP, Wu J, et al. (2009) Ulcerative
colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide
association study. Nat Genet 41: 216–220.
49. McGovern DP, Gardet A, Torkvist L, Goyette P, Essers J, et al. (2010) Genomewide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet
42: 332–337.
50. Anderson CA, Boucher G, Lees CW, Franke A, D’Amato M, et al. (2011) Metaanalysis identifies 29 additional ulcerative colitis risk loci, increasing the number
of confirmed associations to 47. Nat Genet 43: 246–252.
51. Asano K, Matsushita T, Umeno J, Hosono N, Takahashi A, et al. (2009) A
genome-wide association study identifies three new susceptibility loci for
ulcerative colitis in the Japanese population. Nat Genet 41: 1325–1329.
52. Kamio T, Toki T, Kanezaki R, Sasaki S, Tandai S, et al. (2003) B-cell-specific
transcription factor BACH2 modifies the cytotoxic effects of anticancer drugs.
Blood 102: 3317–3322.
53. Grant SF, Qu HQ, Bradfield JP, Marchand L, Kim CE, et al. (2009) Follow-up
analysis of genome-wide association data identifies novel loci for type 1 diabetes.
Diabetes 58: 290–295.
54. Cooper JD, Smyth DJ, Smiles AM, Plagnol V, Walker NM, et al. (2008) Metaanalysis of genome-wide association study data identifies additional type 1
diabetes risk loci. Nat Genet 40: 1399–1401.
55. Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, et al. (2009)
Genome-wide association study and meta-analysis find that over 40 loci affect
risk of type 1 diabetes. Nat Genet 41: 703–707.
56. Plagnol V, Howson JM, Smyth DJ, Walker N, Hafler JP, et al. (2011) Genomewide association analysis of autoantibody positivity in type 1 diabetes cases.
PLoS Genet 7: e1002216. doi:10.1371/journal.pgen.1002216
57. Chu X, Pan CM, Zhao SX, Liang J, Gao GQ, et al. (2011) A genome-wide
association study identifies two new risk loci for Graves’ disease. Nat Genet 43:
897–901.
58. Dubois PC, Trynka G, Franke L, Hunt KA, Romanos J, et al. (2010) Multiple
common variants for celiac disease influencing immune gene expression. Nat
Genet 42: 295–302.
59. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, et al. (2011)
Genetic risk and a primary role for cell-mediated immune mechanisms in
multiple sclerosis. Nature 476: 214–219.
60. Matsui T, Leung D, Miyashita H, Maksakova IA, Miyachi H, et al. (2010)
Proviral silencing in embryonic stem cells requires the histone methyltransferase
ESET. Nature 464: 927–931.
61. Igl W, Polasek O, Gornik O, Knezevic A, Pucic M, et al. (2011) Glycomics meets
lipidomics-associations of N-glycans with classical lipids, glycerophospholipids,
and sphingolipids in three European populations. Mol Biosyst 7: 1852–1862.
62. Cozen W, Li D, Best T, Van Den Berg DJ, Gourraud PA, et al. (2012) A
genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies
risk loci at 6p21.32. Blood 119: 469–475.
63. Chung SA, Taylor KE, Graham RR, Nititham J, Lee AT, et al. (2011)
Differential genetic associations for systemic lupus erythematosus based on antidsDNA autoantibody production. PLoS Genet 7: e1001323. doi:10.1371/
journal.pgen.1001323
64. Hor H, Kutalik Z, Dauvilliers Y, Valsesia A, Lammers GJ, et al. (2010) Genomewide association study identifies new HLA class II haplotypes strongly protective
against narcolepsy. Nat Genet 42: 786–789.
65. Celestino-Soper PB, Shaw CA, Sanders SJ, Li J, Murtha MT, et al. (2011) Use of
array CGH to detect exonic copy number variants throughout the genome in
autism families detects a novel deletion in TMLHE. Hum Mol Genet 20: 4360–
4370.
66. Yashin AI, Wu D, Arbeev KG, Ukraintseva SV (2010) Joint influence of smalleffect genetic variants on human longevity. Aging (Albany NY) 2: 612–620.

16

January 2013 | Volume 9 | Issue 1 | e1003225

Genetic Loci Affecting IgG Glycosylation

79. Wormald MR, Rudd PM, Harvey DJ, Chang SC, Scragg IG, et al. (1997)
Variations in oligosaccharide-protein interactions in immunoglobulin G
determine the site-specific glycosylation profiles and modulate the dynamic
motion of the Fc oligosaccharides. Biochemistry 36: 1370–1380.
80. Mimura Y, Ashton PR, Takahashi N, Harvey DJ, Jefferis R (2007) Contrasting
glycosylation profiles between Fab and Fc of a human IgG protein studied by
electrospray ionization mass spectrometry. J Immunol Methods 326: 116–126.
81. Wang J, Balog CI, Stavenhagen K, Koeleman CA, Scherer HU, et al. (2011) Fcglycosylation of IgG1 is modulated by B-cell stimuli. Mol Cell Proteomics 10:
M110 004655.
82. Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, et al. (2008) SLC2A9 is a
newly identified urate transporter influencing serum urate concentration, urate
excretion and gout. Nat Genet 40: 437–442.
83. Zemunik T, Boban M, Lauc G, Jankovic S, Rotim K, et al. (2009) Genome-wide
association study of biochemical traits in Korcula Island, Croatia. Croat Med J
50: 23–33.
84. McQuillan R, Leutenegger AL, Abdel-Rahman R, Franklin CS, Pericic M, et al.
(2008) Runs of homozygosity in European populations. Am J Hum Genet 83:
359–372.
85. Schoenmaker M, de Craen AJ, de Meijer PH, Beekman M, Blauw GJ, et al.
(2006) Evidence of genetic enrichment for exceptional survival using a family
approach: the Leiden Longevity Study. Eur J Hum Genet 14: 79–84.
86. Ruhaak LR, Uh HW, Beekman M, Koeleman CA, Hokke CH, et al. (2010)
Decreased levels of bisecting GlcNAc glycoforms of IgG are associated with
human longevity. PLoS ONE 5: e12566. doi:10.1371/journal.pone.0012566
87. Aulchenko YS, Ripke S, Isaacs A, van Duijn CM (2007) GenABEL: an R library
for genome-wide association analysis. Bioinformatics 23: 1294–1296.
88. Pe’er I, Yelensky R, Altshuler D, Daly MJ (2008) Estimation of the multiple
testing burden for genomewide association studies of nearly all common variants.
Genet Epidemiol 32: 381–385.
89. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, et al. (2010)
LocusZoom: regional visualization of genome-wide association scan results.
Bioinformatics 26: 2336–2337.
90. Uh HW, Deelen J, Beekman M, Helmer Q, Rivadeneira F, et al. (2011) How to
deal with the early GWAS data when imputing and combining different arrays is
necessary. Eur J Hum Genet 20: 572–576.
91. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, et al. (1982) The 1982
revised criteria for the classification of systemic lupus erythematosus. Arthritis
Rheum 25: 1271–1277.

67. Prasad RB, Hosking FJ, Vijayakrishnan J, Papaemmanuil E, Koehler R, et al.
(2010) Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in
precursor B-cell acute lymphoblastic leukemia of childhood. Blood 115: 1765–
1767.
68. Souabni A, Cobaleda C, Schebesta M, Busslinger M (2002) Pax5 promotes B
lymphopoiesis and blocks T cell development by repressing Notch1. Immunity
17: 781–793.
69. Molokhia M, McKeigue P (2006) Systemic lupus erythematosus: genes versus
environment in high risk populations. Lupus 15: 827–832.
70. Kundu S, Aulchenko YS, van Duijn CM, Janssens AC (2011) PredictABEL: an
R package for the assessment of risk prediction models. Eur J Epidemiol 26:
261–264.
71. Lauc G, Essafi A, Huffman JE, Hayward C, Knežević A, et al. (2010) Genomics
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